Overview

75 or 150 mg Clopidogrel Maintenance Doses Following PCI (ISAR-CHOICE-2)

Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of the study is to test whether an increase of the maintenance dose of clopidogrel from 75 to 150 mg per day results in an additional suppression of ADP-induced platelet aggregation
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Deutsches Herzzentrum Muenchen
Collaborator:
Technische Universität München
Treatments:
Clopidogrel
Ticlopidine
Criteria
Inclusion Criteria:

- Patients with chronic aspirin therapy who are treated with percutaneous coronary
intervention at least 2 hours after administration of a 600 mg loading dose of
clopidogrel

Exclusion Criteria:

- Major alterations of blood count (particularly platelet count < 100x10^9/l,
haemoglobin < 10 mg/dl

- Recent bleeding diathesis

- Presence of a hematologic or malignant disorder

- Oral anticoagulation with coumarin derivates

- Use of glycoprotein (GP) IIb/IIIa antagonists during the intervention or during the
preceding 14 days

- Therapy with clopidogrel within the last 28 days